We collected bone marrow samples from 53 newly diagnosed AML patients and 53 healthy controls between 4 March 2016, and 30 January 2022, at Zhongda Hospital (affiliated with the Southeast University). Written informed consent from all enrolled patients was collected according to the tenets of the Helsinki Declaration, and the study was approved by the Ethics Committee (Zhongda Hospital, Southeast University) (2019ZD-SYLL121-P01, 20 August 2019; 2017ZDSYLL067-P01, 10 August 2017; 2016ZDKYSB062, 4 March 2016) [35 (link)]. Mononuclear cells were isolated from the bone marrow samples using Ficoll.
We obtained primary cells from two recently diagnosed AML patients (referred to as PT1 and PT2) who had high leukocyte counts via leukapheresis. To enrich mononuclear cells, we used Ficoll and then lysed them with a red blood cell lysis buffer from Biosharp, China. We subsequently cultured the primary AML cells in RPMI 1640 containing 10% FBS to use in different experiments.
We obtained primary cells from two recently diagnosed AML patients (referred to as PT1 and PT2) who had high leukocyte counts via leukapheresis. To enrich mononuclear cells, we used Ficoll and then lysed them with a red blood cell lysis buffer from Biosharp, China. We subsequently cultured the primary AML cells in RPMI 1640 containing 10% FBS to use in different experiments.
Free full text: Click here
